Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MOTIF BIO PLC. We currently have 52 research reports from 5 professional analysts.
|01Dec16 05:27||RNS||Issue of Equity|
|25Nov16 11:32||RNS||Holding(s) in Company|
|24Nov16 01:36||RNS||Holding(s) in Company|
|23Nov16 05:12||RNS||Holding(s) in Company|
|23Nov16 04:56||RNS||Closing of public offer|
|18Nov16 12:51||RNS||Confirms successful European placing|
|18Nov16 07:16||RNS||US Pricing and European Placing to raise US$25m|
Frequency of research reports
Research reports on
MOTIF BIO PLC
MOTIF BIO PLC
01 Nov 16
"A flat to marginally positive market is seen for London this morning, with the blue-chip FTSE-100 expected to open up in excess of 15 points. With just a week before election day, politics remained the dominating talking point, with experts declaring that incriminating emails cited by the FBI in their probe into Hillary Clinton's exchanges could be uncovered in the next few days, while she continues to insist there is no case to answer. This kept the markets in a generally nervous mood, with all principal US indices closing fractionally down to cap a disappointing month during which the S&P-500 fell by 1.9% while the NASDAQ lost 2.3%. Asia was in a slightly better mood, with both the Hang Seng and the Shanghai Composite receiving a lift from better than expected official manufacturing PMI data from China, with the index rising to 51.2 for October, up from 50.4 in September, thereby beating expectations for the third straight month. By contrast Japan was in a more sombre mood, having shifted back its target date for achieving a level of 2% inflation from 2017 to 2018 following recent data, although the central bank still left its short-term interest rate target for commercial bank deposits at 0.1%. This left Japan with a fractional loss for the day, while the ASX gave back most of yesterday's gains through weaker commodity plays and financials as the Reserve Bank of Australia left interest rates unchanged at 1.5%. Today both the UK and the US are due to due to release manufacturing PMI figures, while the results season in full swing with a large number of corporates being scheduled to release earning or trading updates this morning, including BP (BP..L), Hastings Group (HSTG.L), MoneySupermarket (MONY.L), Royal Dutch Shell (RDSA.L), Shire (SHP.L), Standard Chartered (STAN.L), Virgin Money (VM..L) and Weir (WEIR.L)." - Barry Gibb, Research Analyst
Tips for 2016 – Q3 Update
10 Oct 16
ACACIA MINING PLC (ACA LN) | BG GROUP PLC (BG/ LN) | DEKELOIL PUBLIC LTD-DI (DKL LN) | DIAGEO (DGE LN) | GLAXOSMITHKLINE (GSK LN) | HSS HIRE GRP PLC (HSS LN) |HUMMINGBIRD RESOURCES PLC (HUM LN) | LLOYDS BANKING GROUP PLC (LLOY LN) | MELROSE INDUSTRIES PLC (MRO LN) | MOTIF BIO PLC (MTFB LN) | MYSQUAR LTD (MYSQ LN) | TULLOW OIL PLC (TLW LN) | UBM PLC (UBM LN) | WHITBREAD (WTB LN)
REVIVE-I timing ahead; CPN renegotiated
08 Sep 16
Motif Bio (LSE: MTFB), is a late clinical stage antibiotic development company. This morning the company announced that its iclaprim phase III clinical trial in acute bacterial skin and skin structure infections (ABSSSI), REVIVE-1, is progressing well with patient enrolment ahead of schedule. The result of this is that data from the trial is now expected to be available in Q2 2017, sooner than previously anticipated H2 2017. The second phase III trial in ABSSSI, REVIVE-2, continues on track with results expected in H2 2017. Motif Bio has also announced the renegotiation of its Convertible Promissory Notes (CPNs) held by Amphion Innovations with a principal value of $3.55m in total. Our riskadjusted fair value estimate for Motif Bio is £204m (188p per share).
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Vp has reported another impressive set of interims, confirming strong growth in most markets and a positive outlook. Recent acquisitions are bedding in well and the full year outturn is set to exceed previous expectations (5%/6% EPS upgrades in FY17/FY18). The recent Capital Markets Day provided a reminder of Vp’s qualities (specialist focus, high returns, strong cash generation) and its growth potential, which in our view are not reflected in a modest <11x P/E rating. We firmly believe the shares are due a re-rating and see intrinsic value in excess of 800p.
Food intolerance driving growth
29 Nov 16
Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious Disease – that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect CD4 for monitoring of HIV positive patients. Interim results highlighted the opportunities to accelerate growth of the business, particularly Allersys, which has drawn attention from its partner.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.